Iris Biotech brings new innovations on the market
The company located in the Bioregion Regensburg was founded in 2001 as a subsidiary of Cfm (Oskar Tropitzsch e.K.). Cfm, founded in 1788 as the first chemical factories in Germany, looks back on over 220 years of expertise. Today the company manufactures enzymes, fermentation products, phytochemicals, pharmaceutical products, laboratory chemicals and toxins. Iris Biotech concentrates their activities in the field of biotechnology and has built up a close cooperation network with universities and other research institutions. Often interesting and useful innovations are worked on here, which unfortunately often do not find their way as marketable products to potentially interested parties. This is exactly where the initiative from IRIS Biotech GmbH and Cfm is being applied. Relevant discoveries can for example be relatively simple molecules, such as alpha-sulfo-beta-alanine, developed by the University of Rouen (France). Newly developed medicines are often hydrophobic and therefore dissolve poorly in the blood. Through conjugation with this molecule the medicines become water soluble and for example can be administered as an injection. A whole product group of over 130 derivates has been developed by the University of Valencia (Spain) with novel so-called PGA (poly-glutamic-acid) structures. These work as a carrier material, which can be attached to several different (!) medicinal molecules. A vehicle for today’s highly topical “Combination Therapy” and “Personalised Medicine”. On the other hand IRIS Biotech GmbH and Cfm deliver reagents for the most diverse research fields. Some of these are so-called “small molecules” important for development of medications and natural materials or toxins. Another research group is working on the destruction of biofilms with the aid of bee venom. Comprehensive cell banks, so-called “libraries” with over 66,000 different marine derivations round off the assortment.
For more information see: